Barry Falgout

Inventor

Add to Portfolio

Stats

Details

Work History

Patent OwnerApplications FiledYear
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
2
2
2
2
1
2004
2009
2011
2013
2017
The United States of America,as represented by the Secretary, Department of Helath and Human Service
1
2017

Inventor Addresses

AddressDuration
Rockville, MDJan 11, 07 - Jan 11, 07
Rockville, MD, USApr 14, 09 - Sep 12, 23

Technology Profile

Technology Matters
A61K: PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 7
A61P: THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 1
C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 1

See more…

Patents / Publication

Patents / Publication #Year of Publication / IssuedTitleCitations
117536272023Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 40
2020/0392,4692020DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1,2,3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1,2,3, AND 40
108370032020Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 40
2018/0010,0992018DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1, 2, 3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 45
RE466412017Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 45

See more…


We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
> Upgrade to our Level for up to -1 portfolios!.